Recently, there has been a lot of interest generated by a new FDA approval. Suzetrigine (Journavx) was recently approved by the US Food and Drug Administration for the management of pain. Although there is a lot of excitement about having a new tool in the toolbox, there are certain limitations that are important to consider. In this episode of Verified Rx, Dave Peterson, pharmacist and drug information specialist for the University of Utah Health joins us to discuss this exciting new non opioid medication.

Guest speaker: 

Dave Peterson, PharmD, BCPS

Drug Information Specialist

University of Utah Drug Information Service

Host: 

Kerry Schwarz, PharmD, MPH

Senior Clinical Manager, Evidence-Based Medicine and Outcomes

Center for Pharmacy Practice Excellence (CPPE)

Show Notes: 

[00:54-02:24] Information about Suzetrigine

[02:25-04:06] What distinguishes suzetrigine from other non-opioid analgesics

[04:07-05:09] What suzetrigine is indicated for

[05:10-06:14] How suzetrigine is being studied

[06:15-08:40] Surgical models and the endpoints that we commonly see in these studies

[08:41-10:25] Making sense of discordant study results

[10:26-12:02] Moving beyond the evidence to real world utilization of suzetrigine

[12:03-14:03] How cost factors into real-world utilization

[14:04-16:21] What Dave is keeping his eye on in terms of clinical concerns

[16:22-17:28] What Dave is excited about with the advent of suzetrigine

Links | Resources:

No pain, much gain?

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed